DOCSLIB.ORG

De Rosa Maria F 200911 Phd Thesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
De Rosa Maria F 200911 Phd Thesis MULTIDRUG RESISTANCE PROTEIN 1 (MDR1) AND GLYCOSPHINGOLIPIDS BIOSYNTHESIS: ADVANTAGES FOR THERAPEUTICS by María Fabiana De Rosa A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Laboratory Medicine and Pathobiology University of Toronto © Copyright by María Fabiana De Rosa (2009) Multidrug Resistance Protein 1 (MDR1) And Glycosphingolipids Biosynthesis: Advantages for Therapeutics Doctor of Philosophy, 2009 María Fabiana De Rosa Department of Laboratory Medicine and Pathobiology University of Toronto ABSTRACT ABC drug transporter, MDR1, is a drug flippase that moves a variety of hydrophobic molecules from the inner to the outer leaflet of the plasma membrane. We have previously reported that MDR1 can function as a glycolipid flippase, being one of the mechanisms responsible for the translocation of glucosylceramide into the Golgi for neutral, but not acidic, glycosphingolipids (GSLs) synthesis. The interplay between GSLs and MDR1 could provide a whole new spectrum of innovative therapeutic options. We found that cell surface MDR1 partially co-localized with globotriaosyl ceramide (Gb3) in MDR1 transfected cells. Inhibition of GSL biosynthesis results in the loss of drug resistance and of cell surface MDR1. We speculated that an association of MDR1 and cell surface GSLs, in particular Gb3, may be functional at the cell surface, as MDR1 partitions into plasma membrane lipid rafts regulating MDR1 function. We therefore tested adamantyl Gb3 (adaGb3), a water soluble analog of Gb3, on MDR1 functions. AdaGb3 was able to inhibit MDR1-mediated rhodamine 123 drug efflux from MDR1 expressing cells, like cyclosporin A (CsA), a classical MDR1 inhibitor. AdaGb3 was also ii able to reverse vinblastine drug resistance in cell culture, whereas adamantyl galactosylceramide had no effect on drug resistance. The strong MDR1 reversal effects of adaGb3, as well as its favourable in vivo features make it a possible choice for inhibition of MDR1 to increase bioavailability of drugs across the intestinal epithelium (De Rosa et al., 2008). Thus, specific GSL analogs provide a new approach to MDR reversal. We have previously shown that MDR1 inhibitor CsA depletes Fabry cell lines of Gb3, the characteristic GSL accumulated in this disease, by preventing its de novo synthesis, and can also deplete Gaucher lymphoid cell lines of accumulated GlcCer (Mattocks et al., 2006). Liver and heart sections of Fabry mice treated with third generation MDR1 inhibitors showed significantly less Gb3 than liver and heart sections of untreated Fabry mice. Thus, MDR1 inhibition offers a potential alternative therapeutic approach not only for Fabry disease given the extraordinary cost of conventional enzyme replacement therapy, but also for other neutral GSL storage diseases, such as Gaucher disease. iii ACKNOWLEDGEMENTS I would like to specially thank my supervisor, Dr. Clifford Lingwood, for his firm and warmth valuable guidance through the fascinating world of cell biology, his constant and unconditional support, and his patience along this project. I would like to thank all my committee members, Dr. David Clarke, Dr. Peter Dirks, and Dr. Reinhart Reithmeier for their support and their brilliant input in this project along these years. I would also like to specially thank my external examine, Dr. Inka Brockhausen, for her valuable appraisal of this thesis. I would also like to thanks all the collaborators in this project, Dr. Shinya Ito, Dr Jeffrey Medin, Bernice Wang, Cameron Ackerley, Aina Tulips, Vanessa Rassaiah, and Xin Fan that bring their invaluable expertise on specific aspects of this project. And finally, I specially would like to thank all past and present members from Dr. Lingwood’s laboratory, especially Dr. Mylvaganam, Beth Binnington and Shirley Thompson that not only bring me their unconditional help but also their constant support in good and not so good times along this project. iv To the beloved memory of my parents, Emma and Jose Maria, for their loving encouragement and support in the pursuit of my career’s dream. To the beloved memory of my parents-in-law, Gloria and specially Ricardo, who always believed in my scientific capabilities and for his support in my decision to pursue a PhD degree. To the beloved memory of my aunt, Maria Elvira, who initiates me in the intriguing and challenging principles of biology. To my beloved husband, for his unconditional love, his loving support and strength in weakest times, for his comforting hugs that hold me tightly and do not let me fall, for sharing side by side the precious and not the so precious moments of this difficult path of pursuing a PhD, and for being that wonderful dad, always but even more when mommy had those abominable deadlines. To my children, Ricardo, Thomas, and my little princess, Gloria that enlighten every minute of my life with their smiles and laughs, and for their big hugs and loving kisses that kept me going even in the most difficult times along this project. To my brothers-in-law, Francisco and Juan Manuel, that make me feel as their special sister and friend and in whom they believe and encourage in the pursuit of her dreams. v TABLE OF CONTENTS ABSTRACT ii ACKNOWLEDGEMENTS iv TABLE OF CONTENTS vi LIST OF ABBREVIATIONS xii LIST OF TABLES xvi LIST OF FIGURES xvii LIST OF SCHEMAS xix CHAPTER ONE. INTRODUCTION 1 1.1. Multidrug Resistance 1 1.1.1. Multidrug Resistance in Cancer 3 1.1.2. Cellular Mechanisms of Multidrug Resistance 4 1.2. ATP-Binding Cassette Transporters 6 1.2.1. Structural Organization and Mechanism of ABC Transporters 8 1.2.2. ABC Transporters in Normal Cells 13 1.2.3. ABC Transporters in Cancer Cells 14 1.2.4. ABC Lipid Transporters 15 1.3. P-glycoprotein – MDR1 16 1.3.1 Structure of P-glycoprotein 17 1.3.2 Mechanism of Action 21 1.3.3 P-glycoprotein Substrates and Inhibitors 25 1.3.4 P-glycoprotein Silent Polymorphisms 30 1.3.5 P-glycoprotein Regulation 32 1.3.6 P-glycoprotein Knockout Mice 35 vi 1.3.7 Other Approaches in Modulation of Multidrug Resistance 37 1.3.8 P-glycoprotein and Stem Cells 39 1.4. Glycosphingolipids 41 1.4.1. Structure of Glycosphingolipids 42 1.4.2. Classification of Glycosphingolipids 43 1.4.3. Biosynthesis and Degradation of Glycosphingolipids 44 1.4.4. Inhibitors of Glycosphingolipids Biosynthesis 48 1.4.5. Lipid Rafts 50 1.4.6. Biological Functions of Glycosphingolipids 52 1.4.7. Globotriaosylceramide 54 1.4.7.1. Structure of Globotriaosylceramide 54 1.4.7.2. Biological Functions of Globotriaosylceramide 55 1.4.7.2.1. Antineoplastic Potential of Verotoxin 62 1.4.8. Lysosomal Storage Diseases 63 1.4.8.1. Pathogenesis 64 1.4.8.2. Fabry and Gaucher Diseases 66 1.4.8.3. Therapeutic Approaches 69 1.5. Multidrug Resistance and Glycosphingolipids 71 1.5.1. MDR1 and Ceramide Metabolism 72 1.5.2. MDR1 and Lipid Flippase 75 1.5.2.1.Alternative Mechanisms for GlcCer Transport into the Golgi 78 1.5.3. MDR1, Cholesterol and Lipid Rafts 79 CHAPTER TWO. HYPOTHESIS AND SPECIFIC AIMS 82 vii 2.1. Rationale 82 2.2. Hypothesis 84 2.2.1. Specific Aims 85 CHAPTER THREE. INHIBITION OF MULTIDRUG RESISTANCE BY ADAMANTYLGb3, A GLOBOTRIAOSYLCERAMIDE ANALOG 86 3.1. Abstract 86 3.2. Introduction 87 3.3. Materials and Methods 89 3.3.1. Materials 89 3.3.2. Cell Culture 89 3.3.3. Immunostaining of MDR1 90 3.3.4. Post-embedding Immunogold Cryolectron Microscopy 91 3.3.5. Neutral Glycolipids Extraction and Analysis 92 3.3.6. Verotoxin 1 Thin Layer Chromatography Overlay 93 3.3.7. Cytotoxicity Assay 93 3.3.8. MDR1-MDCK Raft Isolation 94 3.3.9. Western Blot Analysis of MDR1 95 3.3.10. Rhodamine 123 Efflux Assay 96 3.3.11. Drug Transport 96 3.3.12. Disulfide Cross-Linking Analysis 97 3.4. Results 98 3.4.1. MDR1 in Part Co-localizes with Gb3 98 3.4.2. AdaGb3 Prevents Multidrug Resistance in MDR1-MDCK and SK VLB Cells 102 viii 3.4.3. AdaGb3 Inhibits Cell Surface MDR1 Expression in the Long Term in MDR1-MDCK and SK VLB Cells but Increases Intracellular MDR1 as PPMP, VT1B, and CsA 105 3.4.4. Effect of Adamantyl Analogs on GSL Levels 109 3.4.5. MDR1 Distribution in Lipid Rafts 112 3.4.6. AdaGb3 Inhibits the Efflux of Rhodamine 123 in MDR1-MDCK and SK VLB Cells 113 3.4.7. Verotoxin Treatment Inhibits MDR1-mediated Rhodamine 123 Efflux 114 3.4.8. AdaGb3 Inhibits MDR1-mediated Vinblastine Efflux in Polarized Gastrointestinal Epithelial Cells 115 3.4.9. AdaGb3 Differentially Binds the MDR1 Drug Binding Pocket as Compared with Verapamil and Cyclosporin A 118 3.5. Conclusions 120 CHAPTER FOUR. INHIBITION OF ABC DRUG TRANSPORTER, MDR1, AS POSSIBLE THERAPY FOR FABRY DISEASE 122 4.1. Introduction 122 4.2. Materials and Methods 125 4.2.1. Materials 125 4.2.2. Cell Culture 126 4.2.3. Neutral Glycolipids Extraction and Analysis 126 4.2.4. Gangliosides Extraction and Analysis 126 4.2.5. Verotoxin 1 Thin Layer Chromatography Overlay 127 4.2.6. Metabolic Labeling of MDR1-MDCK Glycosphingolipids 128 ix 4.2.7. Cytotoxicity Assay 128 4.2.8. Treatment of Neonatal Fabry Mice 129 4.2.9. Tissue Extraction of Neutral GSL 130 4.2.10. VT1 Tissue Staining 130 4.2.11. Epitope Unmasking Treatment 131 4.2.12. Anti-Gb3 Tissue Staining 131 4.2.13. HPLC Quantitation of Gb3 132 4.3. Results 133 4.3.1. MDR1 Inhibition in LSD Cell Lines 133 4.3.2. Accmulation of Gb3 in Fabry Mice by 10 Weeks 135 4.3.3.
Load more

Recommended publications
  • Investigating the Survival Response of Staphylococcus Aureus to the Antimicrobial Lipid Sphingosine
    Investigating the Survival Response of Staphylococcus aureus to the Antimicrobial Lipid Sphingosine Yiyun Chen Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy November 2017 Acknowledgement I would like to express my deepest thanks to my supervisor Mal Horsburgh for his invaluable assistance, support and guidance, as well as his smile and patience, throughout my PhD studies. I would like to thank all members in Horsburgh’s group for their kindly support and assistance, especially Josephine Moran who trained me a lot with bioinformatics and data analysis. I would like to thank all members of LabH who created such a great environment for working and studying, with special thanks to lab manager Paul Loughnane who was always around to help. I would like to thank my family for their unconditional support, encouragement and love in my life. Abstract The human skin surface is covered with a lipid film that forms the interface between the viable epidermal layers and outer environment, and influences the colonisation of bacteria. Hydrolysis of the epidermal lipid ceramide via ceramidase yields sphingosine, an antimicrobial lipid that is able to kill staphylococci rapidly. Studies of patients with atopic dermatitis have indicated a correlation between levels of sphingosine and S. aureus colonisation of human skin, yet the contribution of sphingosine to the composition of the human skin microbiome and microbiota colonisation is unclear. This study investigates the effect of the host epidermal antimicrobial lipid D-sphingosine on S. aureus and S. epidermidis, with a focus on discovering components that contribute to survival of the former.
    [Show full text]
  • P2x7 Activation of Non-Primed Myeloid Cells Promotes the Shedding
    P2X7 ACTIVATION OF NON-PRIMED MYELOID CELLS PROMOTES THE SHEDDING OF STIMULATORY MATERIALS WITHIN MICROVESICLES by Louis Michael Thomas B.S., University of Maryland, College Park, 2005 Submitted to the Graduate Faculty of University of Pittsburgh School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2011 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Louis Michael Thomas It was defended on February 2nd, 2011 and approved by Robert J. Binder, Ph.D., Assistant Professor, Department of Immunology Lawrence P. Kane, Ph.D., Associate Professor, Department of Immunology Simon C. Watkins, Ph.D., Professor, Department of Cell Biology and Physiology Ora A. Weisz, Ph.D., Professor, Department of Cell Biology and Physiology & the Renal- Electrolyte Division of the Department of Medicine Dissertation Advisor: Russell D. Salter, Ph.D., Professor, Department of Immunology ii Copyright © by Louis Michael Thomas 2011 iii P2X7 ACTIVATION OF NON-PRIMED MYELOID CELLS PROMOTES THE SHEDDING OF STIMULATORY MATERIALS WITHIN MICROVESICLES Louis Michael Thomas University of Pittsburgh, 2011 There is an increasing need to understand how inflammation is initiated by endogenous factors in the absence of infection. Various diseases such as atherosclerosis and arthritis are shaped by endogenous mediators. In situations such as transplant or trauma where there is extensive amount of tissue damage, endogenous factors can be released to influence inflammation. The modes of activation in which immune cells liberate endogenous factors for incurring immune responses remain elusive. Adenosine triphosphate (ATP) activation of the puringeric receptor P2X7 has been implicated in several immune responses.
    [Show full text]
  • Glucocerebrosidase: Functions in and Beyond the Lysosome
    Journal of Clinical Medicine Review Glucocerebrosidase: Functions in and Beyond the Lysosome Daphne E.C. Boer 1, Jeroen van Smeden 2,3, Joke A. Bouwstra 2 and Johannes M.F.G Aerts 1,* 1 Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Faculty of Science, 2333 CC Leiden, The Netherlands; [email protected] 2 Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Faculty of Science, 2333 CC Leiden, The Netherlands; [email protected] (J.v.S.); [email protected] (J.A.B.) 3 Centre for Human Drug Research, 2333 CL Leiden, The Netherlands * Correspondence: [email protected] Received: 29 January 2020; Accepted: 4 March 2020; Published: 9 March 2020 Abstract: Glucocerebrosidase (GCase) is a retaining β-glucosidase with acid pH optimum metabolizing the glycosphingolipid glucosylceramide (GlcCer) to ceramide and glucose. Inherited deficiency of GCase causes the lysosomal storage disorder named Gaucher disease (GD). In GCase-deficient GD patients the accumulation of GlcCer in lysosomes of tissue macrophages is prominent. Based on the above, the key function of GCase as lysosomal hydrolase is well recognized, however it has become apparent that GCase fulfills in the human body at least one other key function beyond lysosomes. Crucially, GCase generates ceramides from GlcCer molecules in the outer part of the skin, a process essential for optimal skin barrier property and survival. This review covers the functions of GCase in and beyond lysosomes and also pays attention to the increasing insight in hitherto unexpected catalytic versatility of the enzyme. Keywords: glucocerebrosidase; lysosome; glucosylceramide; skin; Gaucher disease 1.
    [Show full text]
  • Targeted Ablation of Arnt in Mouse Epidermis Results in Profound Defects in Desquamation and Epidermal Barrier Function
    Research Article 4901 Targeted ablation of Arnt in mouse epidermis results in profound defects in desquamation and epidermal barrier function Songmei Geng1,*,‡, Alexandre Mezentsev1,‡, Sergey Kalachikov2, Klaus Raith3, Dennis R. Roop4 and Andrey A. Panteleyev1,§ 1Departmnet of Dermatology and 2Columbia Genome Center, Columbia University, New York, NY, USA 3Institute of Pharmaceutics and Biopharmaceutics, Martin Luther University, Halle, Germany 4Departments of Molecular and Cellular Biology and Dermatology, Baylor College of Medicine, Houston, TX, USA *Present address: Department of Dermatology, Second Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of China ‡These authors contributed equally to this work §Author for correspondence (e-mail: [email protected]) Accepted 27 September 2006 Journal of Cell Science 119, 4901-4912 Published by The Company of Biologists 2006 doi:10.1242/jcs.03282 Summary The molecular mechanisms of skin adaptation to the ceramide species in Arnt-null epidermis, suggesting environmental stress are poorly understood. The aryl alterations in lipid metabolism. Continuous retention of hydrocarbon receptor nuclear translocator (Arnt) lies at corneosomes in Arnt-null epidermis that resulted in an the intersection of several crucial adaptive pathways. abnormally dense corny layer and impaired desquamation Nevertheless, its role in adaptation of the skin to was associated with upregulation of Slpi, an inhibitor of environmental stress has just begun to be unraveled. Here stratum corneum chymotryptic enzyme (SCCE) that plays we show that Arnt is expressed in human and mouse skin a key role in corneosome degradation. The functional in a developmentally dependent manner. Targeted K14- defects in Arnt-null mouse epidermis underscore the driven deletion of Arnt in the mouse epidermis resulted in crucial role of Arnt in the maintenance of epidermal early postnatal death, associated with a failure of homeostasis, especially during the perinatal transition to epidermal barrier function.
    [Show full text]
  • Skin Barrier and Lipid Metabolism
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/19370 Please be advised that this information was generated on 2021-10-01 and may be subject to change. Epidermal barrier dysfunction New insights and opportunities for therapeutical intervention Kucháreková M. ■ Epidermal barrier dysfunction: New insights and opportunities for therapeutical intervention Thesis University Medical Centre Nijmegen, the Netherlands With summary in Dutch -224 p, © 2003 ISBN ■ 90-9017339-0 NUR ■ 876 Druk ■ Ipskamp Printpartners, Enschede Vormgeving ■ Milan Tjioe No part of this book may be reproduced by any mechanical, photographic or electronic process, nor may it be stored in a retrieval system, transmitted, or otherwise copied for public or private use, without written permission of the author. Epidermal barrier dysfunction New insights and opportunities for therapeutical intervention Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen Proefschrift ter verkrijging van de graad van doctor aan de Katholieke Universiteit Nijmegen, op gezag van de Rector Magnificus Prof. dr. C.W.P.M. Blom volgens besluit van het College van Decanen in het openbaar te verdedigen op donderdag 4 december 2003 des namiddags om 3.30 uur precies door Martina Kucháreková Geboren op 5 juni 1971 te Zvolen, Slowakije Promotor: Prof. dr. dr. P.C.M. van de Kerkhof Copromotor: Dr. P.G.M. van der Valk Dr.
    [Show full text]
  • Supplemental Table 3
    Supplemental Table 3. Min_max_span_internal Reactions minWT maxWTspanWTminKO maxKO spanKOspanKO/spanWTName Equation Subsystem 2HBO -2 0 2 -3 0 3 1.5 2-Hydroxybutyrate:NAD+[c] : 2hb + nad oxidoreductasePropanoate <==> 2obut Metabolism + h + nadh 2HBt2 -2 0 2 -3 0 3 1.5 2-hydroxybutyrate2hb[e] cotransport + h[e] <==>Transport, with 2hb[c] proton Extracellular + h[c] 2MCITt 0 2 2 0 3 3 1.5 2-methylcitrate2mcit[c] transport <==> via Transport,2mcit[e] diffusion Extracellular 34HPLFM 0 1 1 0 2 2 2 3-(4-hydroxyphenyl-)lactate[m] : 34hpp + Ubiquinoneh formation + nadh --> Biosynthesis34hpl + nad 3DSPHR 0 1 1 0 37.54 37.54 37.536 3-Dehydrosphinganine[c] : 3dsphgn reductase +Sphingolipid h + nadph --> Metabolism nadp + sphgn 4HOXPACDOX(NADP) 0 1 1 0 2 2 2 4-Hydroxyphenylacetaldehyde:NADP+[c] : 4hoxpacdTyrosine + h2o + nadpmetabolism oxidoreductase <==> 4hphac + (2) h + nadph AACTOOR 0 2 2 0 24.58 24.58 12.291 Aminoacetone:oxygen[c] : aact +oxidoreductase(deaminating)(flavin-containing) h2oGly, + o2 Ser, --> Thr h2o2 Metabolism + mthgxl + nh4 AACTtm 0 2 2 0 24.58 24.58 12.291 Aminoacetoneaact[m] transport --> (mitochondrial)aact[c]Transport, Mitochondrial ACACt2m -217 260.7 478.1 -219 149.7 368.6 0.771 Acetoacetate acac[c]mitochondrial + h[c] Transport,<==> transport acac[m] viaMitochondrial +H+ h[m] symport ACACtx -254 0 254.4 -130 0 129.9 0.5105 acetoacetate intracellularacac[c] <==> transport acac[x]Transport, unknown Peroxisomal mechanism ACGAMtly 0 56.44 56.44 0 5 5 0.0886 N-acetyl-glucosamineacgam[l] lysosomal --> acgam[c]Transport, efflux
    [Show full text]
  • Cosmetic Formulation of Skin Care Products DK9685 Half-Series-Title 4/25/06 4:34 PM Page B
    DK9685_half-series-title 4/25/06 4:34 PM Page A Cosmetic Formulation of Skin Care Products DK9685_half-series-title 4/25/06 4:34 PM Page B COSMETIC SCIENCE AND TECHNOLOGY Series Editor ERIC JUNGERMANN Jungermann Associates, Inc. Phoenix, Arizona 1. Cosmetic and Drug Preservation: Principles and Practice, edited by Jon J. Kabara 2. The Cosmetic Industry: Scientific and Regulatory Foundations, edited by Norman F. Estrin 3. Cosmetic Product Testing: A Modern Psychophysical Approach, Howard R. Moskowitz 4. Cosmetic Analysis: Selective Methods and Techniques, edited by P. Boré 5. Cosmetic Safety: A Primer for Cosmetic Scientists, edited by James H. Whittam 6. Oral Hygiene Products and Practice, Morton Pader 7. Antiperspirants and Deodorants, edited by Karl Laden and Carl B. Felger 8. Clinical Safety and Efficacy Testing of Cosmetics, edited by William C. Waggoner 9. Methods for Cutaneous Investigation, edited by Robert L. Rietschel and Thomas S. Spencer 10. Sunscreens: Development, Evaluation, and Regulatory Aspects, edited by Nicholas J. Lowe and Nadim A. Shaath 11. Glycerine: A Key Cosmetic Ingredient, edited by Eric Jungermann and Norman O. V. Sonntag 12. Handbook of Cosmetic Microbiology, Donald S. Orth 13. Rheological Properties of Cosmetics and Toiletries, edited by Dennis Laba 14. Consumer Testing and Evaluation of Personal Care Products, Howard R. Moskowitz 15. Sunscreens: Development, Evaluation, and Regulatory Aspects. Second Edition, Revised and Expanded, edited by Nicholas J. Lowe, Nadim A. Shaath, and Madhu A. Pathak DK9685_half-series-title 4/25/06 4:34 PM Page C 16. Preservative-Free and Self-Preserving Cosmetics and Drugs: Principles and Practice, edited by Jon J.
    [Show full text]
  • Novel Cancer-Related Regulatory Targets for the Signalling Sphingolipids Sphingosine-1-Phosphate and Sphingosylphosphorylcholine
    Kati Kemppainen Kati Novel cancer-related regulatory targets for the signalling sphingolipids sphingosine-1-phosphate and sphingosylphosphorylcholine the signalling sphingolipids sphingosine-1-phosphate for targets regulatory cancer-related Novel Novel cancer-related regulatory targets for the signalling sphingolipids sphingosine-1-phosphate and sphingosylphosphorylcholine Kati Kemppainen Cell Biology Faculty of Science and Engineering ISBN 978-952-12-3380-7 (Print) Åbo Akademi University ISBN 978-952-12-3381-4 (Digital) Turku Doctoral Network in Molecular Biosciences (MolBio) Painosalama Oy – Turku, Finland Turku, Finland, 2016 2016 Novel cancer-related regulatory targets for the signalling sphingolipids sphingosine-1-phosphate and sphingosylphosphorylcholine Kati Kemppainen Cell Biology Faculty of Science and Engineering Åbo Akademi University Turku Doctoral Network in Molecular Biosciences (MolBio) Turku, Finland, 2016 Supervised by Professor Kid Törnquist, PhD Åbo Akademi University Tykistökatu 6, Biocity 20520 Turku, Finland [email protected] Reviewed by Professor Vesa Olkkonen, PhD Minerva Foundation Institute for Medical Research Tukholmankatu 8, Biomedicum 2U 00290 Helsinki, Finland [email protected] and Professor Ilpo Vattulainen, DTech University of Helsinki POB 64 00014 University of Helsinki, Finland [email protected] Opponent Academy professor Elina Ikonen; MD, PhD University of Helsinki Haartmaninkatu 8, Biomedicum 00290 Helsinki, Finland [email protected] ISBN 978-952-12-3380-7 (Print) ISBN 978-952-12-3381-4 (Digital) Painosalama Oy – Turku, Finland Abstract Abstract The signalling sphingolipid sphingosine-1-phosphate (S1P) is necessary for development of the immune system and vasculature and on a cellular level regulates migration, proliferation and survival. Due to these traits S1P has an important role in cancer biology. It is considered a primarily cancer-promoting factor and the enzyme which produces it, sphingosine kinase (SphK), is often over-expressed in tumours.
    [Show full text]
  • Skin Moisturization
    Skin Moisturization edited by James J. Leyden University of Pennsylvania School of Medicine Philadelphia, Pennsylvania Anthony V. Rawlings Unilever Research Bebington, Wirral, United Kingdom Marcel Dekker, Inc. New York • Basel TM Copyright © 2002 by Marcel Dekker, Inc. All Rights Reserved. ISBN: 0-8247-0643-9 This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc. 270 Madison Avenue, New York, NY 10016 tel: 212-696-9000; fax: 212-685-4540 Eastern Hemisphere Distribution Marcel Dekker AG Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland tel: 41-61-261-8482; fax: 41-61-261-8896 World Wide Web http://www.dekker.com The publisher offers discounts on this book when ordered in bulk quantities. For more in- formation, write to Special Sales/Professional Marketing at the headquarters address above. Copyright © 2002 by Marcel Dekker, Inc. All Rights Reserved. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher. Current printing (last digit): 10 9 8 7 6 5 4 3 2 1 PRINTED IN THE UNITED STATES OF AMERICA About the Series The Cosmetic Science and Technology series was conceived to permit discussion of a broad range of current knowledge and theories of cosmetic science and technology. The series is composed of both books written by a single author and edited volumes with a number of contributors. Authorities from industry, academia, and the government participate in writing these books.
    [Show full text]
  • PDF Hosted at the Radboud Repository of the Radboud University Nijmegen
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/19370 Please be advised that this information was generated on 2017-12-06 and may be subject to change. Epidermal barrier dysfunction New insights and opportunities for therapeutical intervention Kucháreková M. ■ Epidermal barrier dysfunction: New insights and opportunities for therapeutical intervention Thesis University Medical Centre Nijmegen, the Netherlands With summary in Dutch -224 p, © 2003 ISBN ■ 90-9017339-0 NUR ■ 876 Druk ■ Ipskamp Printpartners, Enschede Vormgeving ■ Milan Tjioe No part of this book may be reproduced by any mechanical, photographic or electronic process, nor may it be stored in a retrieval system, transmitted, or otherwise copied for public or private use, without written permission of the author. Epidermal barrier dysfunction New insights and opportunities for therapeutical intervention Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen Proefschrift ter verkrijging van de graad van doctor aan de Katholieke Universiteit Nijmegen, op gezag van de Rector Magnificus Prof. dr. C.W.P.M. Blom volgens besluit van het College van Decanen in het openbaar te verdedigen op donderdag 4 december 2003 des namiddags om 3.30 uur precies door Martina Kucháreková Geboren op 5 juni 1971 te Zvolen, Slowakije Promotor: Prof. dr. dr. P.C.M. van de Kerkhof Copromotor: Dr. P.G.M. van der Valk Dr.
    [Show full text]
  • Skin Barrier Function
    Current Problems in Dermatology Editors: P. Itin, G.B.E. Jemec Vol. 49 Skin Barrier Function Editor T. Agner Skin Barrier Function Current Problems in Dermatology Vol. 49 Series Editors Peter Itin Basel Gregor B.E. Jemec Roskilde Skin Barrier Function Volume Editor Tove Agner Copenhagen 26 figures, 6 in color, and 14 tables, 2016 Basel · Freiburg · Paris · London · New York · Chennai · New Delhi · Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney Current Problems in Dermatology Prof. Tove Agner Bispebjerg University Hospital Department of Dermatology Copenhagen (Denmark) Library of Congress Cataloging-in-Publication Data Names: Agner, Tove, editor. Title: Skin barrier function / volume editor, Tove Agner. Other titles: Current problems in dermatology ; v. 49. 1421-5721 Description: Basel ; New York : Karger, 2016. | Series: Current problems in dermatology, ISSN 1421-5721 ; vol. 49 | Includes bibliographical references and indexes. Identifiers: LCCN 2015047342| ISBN 9783318055856 (hard cover : alk. paper) | ISBN 9783318055863 (electronic version) Subjects: | MESH: Skin Physiological Phenomena | Epidermis--physiology Classification: LCC QM481 | NLM WR 102 | DDC 612.7/9--dc23 LC record available at http://lccn.loc.gov/2015047342 Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® and Index Medicus. Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
    [Show full text]